[go: up one dir, main page]

CL2018002727A1 - Medicina obtenida mediante la combinación de agonista fxr y arb - Google Patents

Medicina obtenida mediante la combinación de agonista fxr y arb

Info

Publication number
CL2018002727A1
CL2018002727A1 CL2018002727A CL2018002727A CL2018002727A1 CL 2018002727 A1 CL2018002727 A1 CL 2018002727A1 CL 2018002727 A CL2018002727 A CL 2018002727A CL 2018002727 A CL2018002727 A CL 2018002727A CL 2018002727 A1 CL2018002727 A1 CL 2018002727A1
Authority
CL
Chile
Prior art keywords
arb
fxr
agonist
combining
medicine obtained
Prior art date
Application number
CL2018002727A
Other languages
English (en)
Inventor
Tadashi Namisaki
Hitoshi Yoshiji
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CL2018002727A1 publication Critical patent/CL2018002727A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN AGENTE TERAPÉUTICO PARA NASH QUE INCLUYE: UN AGONISTA DE FXR, PREFERIBLEMENTE ÁCIDO OBETICÓLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO; Y UN ARB O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO.
CL2018002727A 2016-03-28 2018-09-26 Medicina obtenida mediante la combinación de agonista fxr y arb CL2018002727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016064475 2016-03-28

Publications (1)

Publication Number Publication Date
CL2018002727A1 true CL2018002727A1 (es) 2018-12-07

Family

ID=59965591

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002727A CL2018002727A1 (es) 2016-03-28 2018-09-26 Medicina obtenida mediante la combinación de agonista fxr y arb

Country Status (17)

Country Link
US (1) US11419878B2 (es)
EP (1) EP3437659B1 (es)
JP (1) JPWO2017170434A1 (es)
KR (1) KR20180124123A (es)
CN (1) CN109152840A (es)
AU (1) AU2017241559A1 (es)
BR (1) BR112018069789A2 (es)
CA (1) CA3019496A1 (es)
CL (1) CL2018002727A1 (es)
EA (1) EA037330B1 (es)
IL (1) IL262057A (es)
MX (1) MX2018011813A (es)
PH (1) PH12018502109A1 (es)
SG (1) SG11201808607SA (es)
TW (1) TW201733582A (es)
UA (1) UA124499C2 (es)
WO (1) WO2017170434A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210244744A1 (en) * 2018-08-30 2021-08-12 Terns Pharmaceuticals, Inc. Treating liver disorders
EP3876944A4 (en) * 2018-11-08 2022-08-10 Intercept Pharmaceuticals, Inc. METHOD OF USE OF OBETICHOLIC ACID
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
DE102019108825A1 (de) * 2019-04-04 2020-10-08 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbindungen und Verfahren zur Behandlung von Erkrankungen der Leber
KR20210020788A (ko) 2019-08-14 2021-02-24 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
US12528791B2 (en) 2019-08-23 2026-01-20 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
BR112022008639A2 (pt) * 2019-11-08 2022-07-19 Terns Pharmaceuticals Inc Tratamento de distúrbios do fígado
US20220387414A1 (en) * 2019-11-08 2022-12-08 Terns Pharmaceuticals Inc. Treating liver disorders
WO2021113657A1 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Triantennary n-acetylgalactosamine modified hydroxyl polyamidoamine dendrimers and methods of use thereof
US20230105984A1 (en) * 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
IL298145A (en) * 2020-05-13 2023-01-01 Terns Pharmaceuticals Inc Combined treatment of liver disorders
MX2023002308A (es) 2020-08-25 2023-07-11 Lilly Co Eli Polimorfos de un inhibidor de ssao.
EP4210705A4 (en) * 2020-09-11 2024-11-13 Terns Pharmaceuticals, Inc. SOLID DISPERSION FORMULATIONS OF A FXR AGONIST
AU2021359895A1 (en) * 2020-10-15 2023-06-15 Eli Lilly And Company Polymorphs of an fxr agonist
KR20230043773A (ko) 2021-09-24 2023-03-31 (주)샤페론 염증복합체 억제제를 유효성분으로 함유하는, 비알코올성 지방간염, 간 섬유화의 예방, 개선 또는 치료용 약학적 조성물
KR20230052237A (ko) 2021-10-12 2023-04-19 (주)샤페론 타우로데옥시콜산 신규 제제
JPWO2023140350A1 (es) * 2022-01-21 2023-07-27
JP2025541481A (ja) * 2022-12-20 2025-12-18 ティーエイチファーム コーポレーション ナトリウム－グルコース共輸送体－２阻害剤およびアンジオテンシンｉｉ受容体遮断剤を含む非アルコール性脂肪性肝疾患の予防または治療用薬学的組成物
CN117838692A (zh) * 2023-11-17 2024-04-09 上海交通大学医学院附属新华医院 NR1H4激动剂Tropifexor在小儿短肠综合征肠道代偿治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
EP1734970B1 (en) * 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
ES2523591T3 (es) 2006-06-27 2014-11-27 Intercept Pharmaceuticals Inc. Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3789394A1 (en) 2012-06-19 2021-03-10 Intercept Pharmaceuticals, Inc. Crystalline forms c of obeticholic acid
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2014230096C1 (en) * 2013-03-15 2019-08-29 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
KR20160034893A (ko) * 2013-06-13 2016-03-30 패스트 포워드 파머슈티컬스 비.브이. Cd40 시그널링 억제제 및 추가 화합물로서, 상기 추가 화합물은 담즙산, 담즙산 유도체, tgr5-수용체 아고니스트, fxr 아고니스트 또는 이들의 조합이고, 만성 염증의 치료용, 및 위장 암 또는 섬유증의 예방용인, cd40 시그널링 억제제 및 추가 화합물
US9801843B2 (en) * 2013-07-18 2017-10-31 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of ω3 fatty acid
CN105175473B (zh) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途

Also Published As

Publication number Publication date
TW201733582A (zh) 2017-10-01
IL262057A (en) 2018-11-29
MX2018011813A (es) 2019-01-24
US11419878B2 (en) 2022-08-23
UA124499C2 (uk) 2021-09-29
KR20180124123A (ko) 2018-11-20
JPWO2017170434A1 (ja) 2019-01-31
CA3019496A1 (en) 2017-10-05
EP3437659B1 (en) 2023-03-01
PH12018502109A1 (en) 2019-09-23
EP3437659A4 (en) 2019-12-11
US20190247404A1 (en) 2019-08-15
CN109152840A (zh) 2019-01-04
AU2017241559A1 (en) 2018-11-01
WO2017170434A1 (ja) 2017-10-05
EA037330B1 (ru) 2021-03-12
SG11201808607SA (en) 2018-11-29
BR112018069789A2 (pt) 2019-01-29
EA201892119A1 (ru) 2019-02-28
EP3437659A1 (en) 2019-02-06

Similar Documents

Publication Publication Date Title
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
BR112018003984A2 (pt) anticorpos
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
MX2018009175A (es) Agonista fxr derivado de esteroides.
EA201790398A1 (ru) Способы лечения заболевания печени
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
EA201692436A1 (ru) Медицинское применение
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2017000050A1 (es) Terapia de combinación para el cáncer
MX386808B (es) Sistema de suministro de fármaco que comprende un resto de hidrazona y un enlace amida para proporcionar liberción controlada de agentes terapéuticos
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
SV2016005313A (es) Derivados de carboxamida
CO2019002245A2 (es) Combinación de agonistas de fxr
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
CL2016003271A1 (es) Métodos para tratar infecciones
UY36562A (es) Metodo para la administración de droga